Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Breast Cancer
Erschienen in: Breast Cancer 1/2015

01.01.2015 | Special Feature

Japan Breast Cancer Society clinical practice guideline for surgical treatment of breast cancer

verfasst von: Yoshifumi Komoike, Masafumi Inokuchi, Toshikazu Itoh, Kaoru Kitamura, Goro Kutomi, Takehiko Sakai, Hiromitsu Jinno, Noriaki Wada, Shozo Ohsumi, Hirofumi Mukai

Erschienen in: Breast Cancer | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Excerpt

From 1972 to 1989, 6 randomized controlled trials (RCT) of breast-conserving surgery followed by radiotherapy and radical mastectomy were performed. The two groups did not significantly differ in long-term survival rate after 20 years [1, 2]. Breast-conserving therapy is now a standard of care for Stage I and II breast cancer. As for ductal carcinoma in situ (DCIS), no RCTs compared breast-conserving therapy with mastectomy, but many published case series, reviews and meta-analyses showed good local control rates and high overall survival (OS) results [3]. Most Stage 0–II breast cancers are candidates for breast-conserving therapy, but as the EBCTCG’s meta-analysis showed that local recurrence adversely affected survival rates [4], caution is warranted regarding indication or contraindication for breast-conservation therapy and extent of resection. …
Literatur
1.
Fisher B, Anderson S, Bryant J, Margolese G, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–41.PubMedCrossRef
2.
Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227–32.PubMedCrossRef
3.
Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010;102(3):170–8.PubMedCrossRef
4.
Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.PubMedCrossRef
5.
Silverstein MJ, Lagios MD, Craig PH, Waisman JR, Lewinsky BS, Colburn WJ, et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer. 1996;77(11):2267–74.PubMedCrossRef
6.
Singletary SE. Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy. Am J Surg. 2002;184:383–93.PubMedCrossRef
7.
Houssami N, Macaskill P, Marinovich ML, Dixon JM, Irwig L, Brennan ME, et al. Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy. Eur J Cancer. 2010;46:3219–32.PubMedCrossRef
8.
Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008;26:814–9.PubMedCrossRef
9.
Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:188–94.PubMedCrossRef
10.
Nakamura S, Kenjo H, Nishio T, Kazama T, Doi O, Suzuki K. Efficacy of 3D-MR mammography for breast-conserving surgery after neoadjuvant chemotherapy. Breast Cancer. 2002;9:15–9.PubMedCrossRef
11.
Akashi-Tanaka S, Fukutomi T, Sato N, Iwamoto E, Watanabe T, Katsumata N, et al. The use of contrast-enhanced computed tomography before neoadjuvant chemotherapy to identify patients likely to be treated safely with breast-conserving surgery. Ann Surg. 2004;239:238–43.PubMedCentralPubMedCrossRef
12.
Ishitobi M, Komoike Y, Nakahara S, Motomura K, Koyama H, Inaji H. Repeat lumpectomy for ipsilateral breast tumor recurrence after breast-conserving treatment. Oncology. 2011;81:381–6.PubMedCrossRef
13.
Lanitis S, Tekkis PP, Sgourakis G, Dimopoulos N, Al Mufti R, Hadjiminas DJ. Comparison of skin-sparing mastectomy versus non-skin-sparing mastectomy for breast cancer: a meta-analysis of observational studies. Ann Surg. 2010;251(4):632–9.PubMedCrossRef
14.
Paepke S, Schmid R, Fleckner S, Paepke D, Niemeyer M, Schmalfeldt B, et al. Subcutaneous mastectomy with conservation of the nipple–areola skin: broadening the indications. Ann Surg. 2009;250(2):288–92.PubMedCrossRef
15.
Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(8):567–75.PubMedCrossRef
16.
Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival-a Bayesian meta-analysis. Ann SurgOncol. 1999;6(1):109–16.
17.
Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol. 2006;7(12):983–90.PubMedCrossRef
18.
Zavagno G, De Salvo GL, Scalco G, Bozza F, Barutta L, Del Bianco P, GIVOM Trialists, et al. A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer:results of the Sentinella/GIVOM trial. Ann Surg. 2008;247(2):207–13.PubMedCrossRef
19.
Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Constantino JP, et al. Sentinel lymph node resection compared with conventional axillary lymph node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927–33.PubMedCentralPubMedCrossRef
20.
Rosen PP, Lesser ML, Kinne DW, Beattie EJ. Discontinuous or “skip” metastases in breast carcinoma. Analysis of 1228 axillary dissections. Ann Surg. 1983;197(3):276–83.PubMedCentralPubMedCrossRef
21.
Veronesi U, Rilke F, Luini A, Sacchini V, Galimberti V, Campa T, et al. Distribution of axillary node metastases by level of invasion. An analysis of 539 cases. Cancer. 1987;59(4):682–7.PubMedCrossRef
22.
Danforth DN, Findlay PA, McDonald HD, Lippman ME, Reichert CM, d’Angelo T, et al. Complete axillary lymph node dissection for stage I-II carcinoma of the breast. J Clin Oncol. 1986;4(5):655–62.PubMed
23.
Fowble B, Solin LJ, Schultz DJ, Goodman RL. Frequency, sites of relapse, and outcome of regional node failures following conservative surgery and radiation for early breast cancer. Int J Radiat Oncol Biol Phys. 1989;17(4):703–10.PubMedCrossRef
24.
Fleissig A, Fallowfield LJ, Langridge CI, Johnson L, Newcombe RG, Dixon JM, et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomized trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat. 2006;95(3):279–93.PubMedCrossRef
25.
Noguchi M, Motomura K, Imoto S, Miyauchi M, Sato K, Iwata H, et al. A multicenter validation study of sentinel lymph node biopsy by the Japanese Breast Cancer Society. Breast Cancer Res Treat. 2000;63(1):31–40.PubMedCrossRef
26.
Yen TW, Hunt KK, Ross MI, Mirza NQ, Babiera GV, Meric-Bernstam F, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ:a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am CollSurg. 2005;200(4):516–26.
27.
Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis:a randomized clinical trial. JAMA. 2011;305(6):569–75.PubMedCrossRef
28.
Vl Galimberti, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, International Breast Cancer Study Group Trial 23–01 investigators. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297–305.CrossRef
29.
Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006;93(5):539–46.PubMedCrossRef
30.
Kuehn T, Bauerfeind IGP, Fehm T, Fleige B, Helms G, Lebeau A, et al. Sentinel lymph node biopsy before or after neoadjuvant chemotherapy—final results from the prospective german, multiinstitutional SENTINA-Trial. Cancer Res. 2012;72(24 supplement 3):95s.
31.
Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy—results from the ACOSOG Z1071 trial. Cancer Res. 2012;72(24 supplement 3):94s.
32.
Torresan RZ, Cabello C, Conde DM, Brenelli HB. Impact of the preservation of the intercostobrachial nerve in axillary lymphadenectomy due to breast cancer. Breast J. 2003;9(5):389–92.PubMedCrossRef
33.
McNeely ML, Campbell K, Ospina M et al. Exercise interventions for upper-limb dysfunction due to breast cancer treatment. Cochrane Database Syst Rev; 2010.
34.
Kitamura K, Iwase S, Kuroda Y, Yamaguchi T, Yamamoto D, Odagiri H, et al. A practice guideline for the management of lymphoedema. J Lymphoedema. 2011;6(2):60–71.
35.
Nakajima H, Fujiwara I, Mizuta N, Sakaguchi K, Hachimine Y, Magae J. Video-assisted skin-sparing breast-conserving surgery for breast cancer and immediate reconstruction with autologous tissue: clinical outcomes. Ann Surg Oncol. 2009;16(7):1982–9.PubMedCrossRef
36.
Ito T, Oura S, Yamamoto N, Nagamine S, Takahashi M, Tanino H, et al. Radiofrequency ablation (RFA) of breast cancer: A multicenter retrospective analysis. J Clin Oncol 2012;30(15): suppl; abstr 1119.
37.
Sharma R, Rourke LL, Kronowitz SJ, Oh JL, Lucci A, Litton JK, et al. Management of local-regional recurrence following immediate breast reconstruction in patients with early breast cancer treated without postmastectomy radiotherapy. Plast Reconstr Surg. 2011;127(5):1763–72.PubMedCrossRef
38.
Venus MR, Prinsloo DJ. Immediate breast reconstruction with latissimusdorsi flap and implant: audit of outcomes and patient satisfaction survey. J Plast Reconstr Aesthet Surg. 2010;63(1):101–5.PubMedCrossRef
39.
Prabhu R, Godette K, Carlson G, Losken A, Gabram S, Fasola C, et al. The Impact of skin-sparing mastectomy with immediate reconstruction in patients with Stage III breast cancer treated with neoadjuvant chemotherapy and postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2012;82(4):e587–93.PubMedCrossRef
40.
Giacalone PL, Rathat G, Daures JP, Benos P, Azria D, Rouleau C. New concept for immediate breast reconstruction for invasive cancers: feasibility, oncological safety and esthetic outcome of post-neoadjuvant therapy immediate breast reconstruction versus delayed breast reconstruction: a prospective pilot study. Breast Cancer Treat. 2010;122:439–51.CrossRef
41.
Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery. 2002;132(4):620–6.PubMedCrossRef
42.
Shien T, Kinoshita T, Shimizu C, Hojo T, Taira N, Doihara H, et al. Primary tumor resection improves the survival of younger patients with metastatic breast cancer. Oncol Rep. 2009;21(3):827–32.PubMed
43.
Soran A, Ozbas S, Kelsey SF, Gulluoglu BM. Randomized trial comparing locoregional resection of primary tumor with no surgery in stage IV breast cancer at the presentation (Protocol MF07-01): a study of Turkish Federation of the National Societies for Breast Diseases. Breast J. 2009;15(4):399–403.PubMedCrossRef
44.
Pergolizzi S, Settineri N, Russi E, Maisano R, Adamo V, Santacaterina A, et al. Supraclavicular lymph node metastases (SLM) from breast cancer as only site of distant disease: has radiology any role? Anticancer Res. 1997;17(30):2303–8.PubMed
45.
Shen S-C, Liao C-H, Lo Y-F, Tsai H-P, Kuo W-L, Yu C–C, et al. Favorable outcome of secondary axillary dissection in breast cancer patients with axillary nodal relapse. Ann Surg Oncol. 2012;19(4):1122–8.PubMedCrossRef
46.
Welter S, Jacobs J, Krbek T, Totsch M, Stamatis G. Pulmonary metastases of breast cancer. When is resection indicated? Eur J Cardiothorac Surg. 2008;34(6):1228–34.PubMedCrossRef
47.
Dürr HR, Müller PE, Lenz T, Baur A, Jansson V, Refior HJ. Surgical treatment of bone metastases in patients with breast cancer. Clin Orthop Relat Res. 2002;396:191–6.PubMedCrossRef
48.
Hoffmann K, Franz C, Hinz U, Schirmacher P, Ferfarth C, Eichbaum M, et al. Liver resection for multimodal treatment of breast cancer metastases: identification of prognostic factors. Ann Surg Oncol. 2010;17(6):1546–54.PubMedCrossRef
49.
Altundag K, Bondy ML, Mirza NQ, Kau SW, Broglio K, Hortobagyi GN, et al. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer. 2007;110(12):2640–7.PubMedCrossRef
50.
Mahmoud-Ahmed AS, Suh JH, Lee SY, Crownover RL, Barnett GH. Results of whole brain radiotherapy in patients with brain metastases from breast cancer: a retrospective study. Int J Radiat Oncol Biol Phys. 2002;54(3):810–7.PubMedCrossRef
51.
Jenkinson MD, Haylock B, Shenoy A, Husband D, Javadpour M. Management of cerebral metastasis: evidence-based approach for surgery, stereotactic radiosurgery and radiotherapy. Eur J Cancer. 2011;47(5):649–55.PubMedCrossRef
52.
Hind D, Wyld L, Beverley CB, Reed MW. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev 2006;(1): CD004272.
53.
Wagman LD, Tegtmeier B, Beatty JD, Kloth DD, Kokal WA, Riihimaki DU, et al. A prospective, randomized double-blind study of the use of antibiotics at the time of mastectomy. Surg Gynecol Obstet. 1990;170(1):12–6.PubMed
54.
Gupta R, Sinnett D, Carpenter R, Preece PE, Royle GT. Antibiotic prophylaxis for post-operative wound infection in clean elective breast surgery. Eur J Surg Oncol. 2000;26(4):363–6.PubMedCrossRef
55.
de Bresser J, de Vos B, van der Ent F, Hulsewe K. Breast MRI in clinically and mammographically occult breast cancer presenting with an axillary metastasis: a systematic review. Eur J Surg Oncol. 2010;36(2):114–9.PubMedCrossRef
56.
Varadarajan R, Edge SB, Yu J, Watroba N, Janarthanan BR. Prognosis of occult breast carcinoma presenting as isolated axillary nodal metastasis. Oncology. 2006;71(5–6):456–9.PubMedCrossRef
57.
van Ooijen B, Bontenbal M, Henzen-Logmans SC, Koper PC. Axillary nodal metastases from an occult primary consistent with breast carcinoma. Br J Surg. 1993;80(10):1299–300.PubMedCrossRef
58.
Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(3):237–51.PubMedCrossRef
59.
Grover VK, Mathew PJ, Yaddanapudi S, Sehgal S. A single dose of preoperative gabapentin for pain reduction and requirement of morphine after total mastectomy and axillary dissection: randomized placebo-controlled double-blind trial. J Postgrad Med. 2009;55(4):257–60.PubMedCrossRef
60.
Jang JH, Choi MY, Lee SK, et al. Clinicopathologic risk factors for the local recurrence of phyllodes tumors of the breast. Ann Surg Oncol. 2012;19:2612–7.PubMedCrossRef
61.
Kapiris I, Nasiri N, A’Hern R, et al. Outcome and predictive factors of local recurrence and distant metastases following primary surgical treatment of high-grade malignant phyllodes tumours of the breast. European J Surg Oncol: J Eur Soc Surgical Oncol Br Assoc Surg Oncol. 2001;27:723–30.CrossRef
Metadaten
Titel
Japan Breast Cancer Society clinical practice guideline for surgical treatment of breast cancer
verfasst von
Yoshifumi Komoike
Masafumi Inokuchi
Toshikazu Itoh
Kaoru Kitamura
Goro Kutomi
Takehiko Sakai
Hiromitsu Jinno
Noriaki Wada
Shozo Ohsumi
Hirofumi Mukai
Publikationsdatum
01.01.2015
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 1/2015
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-014-0558-7

Weitere Artikel der Ausgabe 1/2015

Breast Cancer 1/2015 Zur Ausgabe

Special Feature

The Japanese Breast Cancer Society Clinical Practice Guideline for pathological diagnosis of breast cancer

Original Article

Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy

Special Feature

The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer

Original Article

Early removal of drains and the incidence of seroma after breast surgery

Case Report

A case of femoral diaphyseal fracture after long-term treatment with zoledronic acid

Special Feature

The Japanese Breast Cancer Society clinical practice guideline for radiotherapy of breast cancer

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise